Interim report January - March 2010 Continuous strong underlying growth with good profitability and cash flow • Growth in local currency was 15 percent. Sales amounted to SEK 75 (72) million, corresponding to an increase of 5 percent in SEK. • Operating income before research and development costs increased by 21 percent and amounted to SEK 21 (17) million. • Operating income (EBIT) increased by 14 percent and amounted to SEK 10 (9) million. The operating margin was 13 (12) percent. • The Group's net income amounted to SEK 10 (8) million, which gives earnings per share of SEK 0.50 (0.43) • The cash flow from operating activities was SEK 7 (-3). • The clinical study on STEEN Solution™ was completed during the period. • A collaboration agreement was entered into with Finn-Medi Research Ltd concerning the Stem Cells area. April 27, 2010 Gothenburg Magnus Nilsson CEO Queries should be addressed to: Magnus Nilsson, CEO; phone +46 31 721 80 61 Eva Nilsagård, CFO, phone +46 31 721 80 13 ________________________________________________________________________________ ________________________________________________ Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes. Vitrolife today has approximately 170 employees and the company's products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan. Production facilities are located in Sweden and USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap. ________________________________________________________________________________ _________________________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com. Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Tuesday April 27, 2010 at 8:30 am CET. This is a translation of the Swedish version of the notice. When in doubt, the Swedish wording prevails.